Moderna Collaboration and License Agreement - Narratives (Details) $ in Thousands	1 Months Ended	12 Months Ended
	Jan. 31, 2022 USD ($) product target	Dec. 31, 2023 USD ($) obligation	Dec. 31, 2022 USD ($)
Moderna Collaboration and License Agreement
Research and development services as collaboration revenues		$ 14,900	$ 9,800
Collaboration revenues		$ 14,919	$ 9,834
Collaboration and License Agreement | Research and Development Services
Moderna Collaboration and License Agreement
Upfront non-refundable payment received	$ 45,000
Variable consideration	$ 73,900
Term of contract	5 years
Noncurrent portion of deferred revenue	$ 45,000
Collaboration and License Agreement | Moderna
Moderna Collaboration and License Agreement
Maximum of research targets | target	12
Number of research targets, designate as development targets | target	12
Number of research targets designated | target	5
Collaboration and License Agreement | Moderna | Research and Development Services
Moderna Collaboration and License Agreement
Upfront non-refundable payment received	$ 45,000
Number of products developed and commercialized | product	12
Minimum commitment to reimburse research and development costs	$ 10,000
Period of reimbursement of research and development costs	3 years
Number of performance obligations | obligation		2
Collaboration and License Agreement | Moderna | Minimum | Research and Development Services
Moderna Collaboration and License Agreement
Amount receivable per product	$ 247,000
Collaboration and License Agreement | Moderna | Maximum | Research and Development Services
Moderna Collaboration and License Agreement
Amount receivable per product	$ 253,000
Moderna License Agreement
Moderna Collaboration and License Agreement
Collaboration revenues		$ 24,700